Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents (Open) - JADPRO
Newly Diagnosed Myeloma in 2020 | American Society of Clinical Oncology Educational Book
Clinical trials of single-agent bortezomib | Download Table
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy | Leukemia
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | NEJM
European perspective on multiple myeloma treatment strategies: update following recent congresses. - Abstract - Europe PMC
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma - Journal of Thoracic Oncology
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma | NEJM
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | NEJM
Bortezomib in multiple myeloma: treatment approach and outcomes - ScienceDirect
How Effective is VELCADE® (bortezomib)?
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
![Top 10 Velcade Clinical Trials [2022 Studies] | Power](https://pwr-og-img.withpower.com/Apply%20to%20this%20Phase%202%20clinical%20trial%20treating%20Haematological%20Malignancies,%20Hematologic%20Neoplasms:%0A%0ABortezomib%20for%20Hematologic%20Neoplasms.png?md=1 "Top 10 Velcade Clinical Trials [2022 Studies] | Power")
Top 10 Velcade Clinical Trials [2022 Studies] | Power
Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis | PLOS ONE
Bortezomib (Velcade™) in the Treatment of Multiple Myeloma | Semantic Scholar
BELLINI Trial at ASCO 2020 | Int'l Myeloma Foundation
Clinical trials of bendamustine with or without bortezomib | Download Table
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial - ScienceDirect
Levine Cancer Institute Myeloma Trials
OPTIMISMM Trial - Capsule Summary Slidesets - Hematologic Malignancies - 2018 ASCO Annual Meeting - Oncology - Clinical Care Options
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Clinical trials of bortezomib in multiple drug combination regimens | Download Table
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial - The Lancet Oncology
VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma | 2 Minute Medicine
